Background 60 Antimicrobial resistance is a major issue in the Shigellae, particularly as a specific multidrug resistant 61 (MDR) lineage of Shigella sonnei (lineage III) is becoming globally dominant. Ciprofloxacin is a 62 recommended treatment for Shigella infections. However, ciprofloxacin resistant S. sonnei are being 63 increasingly isolated in Asia, and sporadically reported on other continents. 64
Multicentre Study (GEMS), a large prospective case-control study focusing on mild and severe 90 paediatric diarrheal illnesses in sub-Saharan Africa and South Asia, found that Shigella (a genus of 91
Gram-negative enteric bacteria) were amongst the top four most prevalent diarrhoeal pathogens in 92 these settings [2] . The most recent estimates suggest that Shigella infections account for around 125 93 million cases of diarrhoea annually, with the majority occurring in children in low income countries 94 [3] . There are four Shigella species (dysenteriae, boydii, flexneri and sonnei), but the overwhelming 95 majority of the current global burden is presently caused by S. sonnei and S. flexneri. Present-day 96 international epidemiology of the various Shigella species is particularly intriguing, as S. sonnei is 97 replacing S. flexneri as the most common cause of shigellosis worldwide; this pattern is accentuated in 98 regions undergoing rapid economic development [4, 5] , where S. flexneri dominated as recently as a 99 decade ago. 100 101 Shigella infections are characterised by the invasion and disruption of the epithelial cells lining the 102 gastrointestinal mucosa, resulting in mucous and/or bloody diarrhoeal discharge. Although shigellosis 103 is typically self-limiting, antimicrobial treatment is used to prevent complications, reduce dysenteric 104 discharge and curb post-symptomatic faecal shedding [6, 7] . Consequently, resistance to 105 antimicrobials restricts treatment options, placing vulnerable individuals suffering from shigellosis at 106 increased risk of complications and increasing the likelihood of protracted faecal shedding. One of the 107 current recommended first-line treatments for shigellosis is the fluoroquinolone, ciprofloxacin [8] . 108
The fluoroquinolones target the DNA gyrase, a type II topoisomerase that is essential for bacterial 109 DNA replication and transcription [9] . 110 111 Antimicrobial resistance is an emerging global issue in S. sonnei, with a specific multidrug resistant 112 (MDR) lineage (III) now dominating internationally. Further, organisms belonging to lineage III 113 appear to be highly proficient at acquiring resistance to additional antimicrobials (including third 114 generation cephalosporins) when they are introduced into new locations [10] . However, given their 115 common usage and broad spectrum of activity, resistance against the fluoroquinolones is the most 116 concerning. Since the first isolation of S. sonnei with reduced susceptibility to ciprofloxacin in Japan 117 
Strain collection 132
Aiming to investigate the current international upsurge in ciprofloxacin resistant S. sonnei in detail, 133
we gathered a collection of 60 contemporary ciprofloxacin resistant S. sonnei from six countries for 134 whole genome sequencing. The isolates originated from Asian countries with a high incidence of 135 shigellosis (Vietnam, n=11; Bhutan, n=12; Thailand, n=1; Cambodia, n=1), as well as isolates from 136 countries with a low incidence of shigellosis (Australia, n=19; Ireland, n=16). Twelve additional 137 ciprofloxacin susceptible S. sonnei sequences from these settings were also included for phylogenetic 138 context. All strains were isolated independently between 2010 and 2015; details of the isolates used in 139 this study are shown in Table 1 . 140 141 6
The S. sonnei isolates from countries with a high incidence of shigellosis in Asia were collected 142 through diarrhoeal disease surveillance in Bhutan and Thailand and as part of on-going, local IRB 143 approved, hospital based studies in Ho Chi Minh City, Vietnam and Siem Reap, Cambodia [14] . The 144 target patient group for these studies were/are generally hospitalised children aged less than five years 145 residing in close proximity to the study centres. The ciprofloxacin resistant S. sonnei from countries 146 with a low incidence of shigellosis (outside Asia) were collected and characterized by the National 147
Salmonella, Shigella and Listeria monocytogenes Reference Laboratory, Galway, Ireland, and the 148 Microbiological Diagnostic Unit Public Health Laboratory, Melbourne, Australia. These isolates were 149 generally, but not exclusively, obtained from patients reporting recent travel to countries with a high 150 incidence of shigellosis in Asia (Table 1 ). Susceptibility to ciprofloxacin was determined by either 151 disk diffusion, E-test, agar dilution or broth microdilution, depending on the collaborating institution, 152 and susceptibility breakpoints were interpreted according to the European Committee on 153 Antimicrobial Susceptibility Testing (http://www.eucast.org/clinical_breakpoints). Namely, resistance 154 was determined as strains with a zone of inhibition ≤15 mm (5 µg disc) and/or a Minimum Inhibitory 155 Concentration (MIC) >2 µg/ml against ciprofloxacin; the various location specific methods and 156 resulting data are described in Table 1 . 157 158
Genome sequencing and analysis 159
All isolated S. sonnei were sub-cultured and subjected to DNA extraction prior to whole genome 160 sequencing on various Illumina platforms to produce pair-ended short read sequence; the specific 161 sequencing system and the resulting public database numbers are shown in Table 1 . We additionally 162 included 14 S. sonnei sequences from organisms isolated in the USA and deposited in the 163 GenomeTrackr Project (NCBI BioProject number PRJNA218110). All sequences were mapped to the 164 S. sonnei Ss046 reference sequence (Accession number: NC_007384) using SMALT (version 0.7.4) 165
and SNPs were called against the reference and filtered using SAMtools Central Asia III sequences sourced from our previous global study ( Figure 1B) [20]. The majority of 196 the Central Asia III isolates carried more than three antimicrobial resistance genes, encoding resistance to a wide range of first-line drugs including tetracycline, streptomycin and co-trimoxazole. 198
We additionally examined the genome sequence data for mutations in the Quinolone Resistance 199
Determining Region (QRDR) within the DNA gyrase gene (gyrA) and the topoisomerase IV gene 200 (parC), the regions encoding the target residues for fluoroquinolone activity. Overlaying these 201 mutations on the phylogenetic tree indicated that the gyrA-S83L mutation, the first sequential 202 mutation which confers reduced susceptibility against fluoroquinolones, has arisen independently 203 within the Central Asia III clade on at least four separate occasions ( Figure 1B) . Amongst the isolates 204 examined here for the first time, extensive resistance to ciprofloxacin can be attributed to a single 205 clonal emergence event, via the sequential accumulation of gyrA-S83L followed by parC-S80I and 206 gyrA-D87G, except for a single outlier that was isolated in Australia ( Figure 1B) . These three QRDR 207 mutations were also shared by ten phenotypically uncharacterized S. sonnei from the USA, thus 208 providing genotypic evidence for ciprofloxacin resistance. The single outlier isolate shares the gyrA-209 S83L and parC-S80I QRDR mutations of the other ciprofloxacin resistant isolates, but harbours gyrA-210 D87N rather than a gyrA-D87G, and is within a closely related out group of the major ciprofloxacin 211 resistant clone ( Figure 1B) . 212 213
South Asia as a hub of fluoroquinolone resistant Shigella sonnei 214
We additionally mapped the country of isolation and patient travel history onto the Central Asia III 215 phylogeny to investigate the geographical structure of the clade ( Figure 1B ). For the ciprofloxacin 216 resistant S. sonnei isolated from countries with a low incidence of shigellosis (Ireland, Australia and 217 USA) and for which data on recent travel history was confirmed (27/45; 60%), India was the most 218 commonly reported travel destination (21/27; 78%). The majority of the isolates associated with travel 219 to India clustered closely with strains isolated in neighbouring Bhutan. These data suggest that South 220
Asia is the primary source of ciprofloxacin resistant S. sonnei that have increasingly been isolated 221 both inside and outside of Asia in recent years. Further, greater genetic diversity was observed within 222 the South Asian S. sonnei than within the other sampled countries ( Figure 1B ), suggesting that this 223 region acts as the most likely geographical source population. 224
Our data also show evidence of regional diversification of ciprofloxacin resistant S. sonnei within 226
Asia. The phylogenetic structure is highly suggestive of a clonal expansion of ciprofloxacin resistant 227 S. sonnei in Southeast Asia, specifically within Vietnam, as indicated by a long branch with 100% 228 bootstrap support ( Figure 1B) . We additionally noted that S. sonnei nested within this clonal 229 expansion were also isolated from travellers returning from countries including Cambodia and resistance was inconsistent. However, PFGE in this context did not offer sufficient granularity to link 269 all of the isolates or provide sufficient resolution into the regional evolution of S. sonnei. Our 270 phylogenetic analyses show that this pulsotype is associated with a phylogenetic lineage, supporting 271 the notion that this pulsotype actually represents a widespread and pervasive subclade of Central Asia 272
III. 273 274
This work has limitations. First, the lack of historical organisms from South Asia restricts our 275 inference to only the contemporary situation. Further, additional present organisms from other settings 276 would have improved our understanding of the current geographical spread of this clonal group. 277
Notwithstanding these limitations, whole genome sequencing of these geographically disparate 278 organisms has provided data at the highest resolution for deciphering the emergence and international 279 spread of ciprofloxacin resistant S. sonnei. Future studies interrogating extensive spatial and temporal 280 collections of ciprofloxacin resistant S. sonnei, as well as the S. sonnei diversity specific to South Asia prior to and during the emergence of antimicrobial resistance, are essential to further elucidate the 282 origins and epidemiological dynamics of these populations. These supplementary investigations will 283 greatly aid our efforts in controlling the spread of the current ciprofloxacin resistant clone and to 284 prevent future emergent antimicrobial resistant bacterial populations. 285
286
In conclusion, the international surge of ciprofloxacin resistant S. sonnei clone poses a substantial 287 global health challenge, and our data show this threat is not only manifested in sporadic cases from 288 returning travellers but also the establishment of endemic transmission in new settings. The latter is 289 already evident in high shigellosis incidence areas such as Southeast Asia. Therefore, integrative 290 efforts from both the research community and public health authorities should be prioritised to track, 291 monitor and prevent the international spread of this key enteric pathogen. 292 293
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